CHAPTER 1 INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2 RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1. Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3 MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4 MARKET DYNAMICS
4.1. Market Drivers & Opportunities
4.1.1. Technological advancements in the field of HLA typing coupled with increased
funding, research grants and public-private investments
4.1.2. Growing number of solid organ, soft-tissue, and stem cell transplantation procedures
4.1.3. Improving healthcare infrastructure across developing economies
4.1.4. Technological shift from serological assays to gene-based HLA profiling
4.1.5. Increase in the transplantation procedures owing to the rising number of organ
failures
4.2. Market Restraints & Challenges
4.2.1. Limited medical reimbursements for organ donation and transplantation procedures
4.2.2. The high cost of NGS and PCR-based devices
4.2.3. The significant gap between the number of organs donated and organs required annually
CHAPTER 5 GLOBAL HLA TYPING FOR TRANSPLANT MARKET – BY PRODUCT & SERVICES
5.1. Instruments
5.2. Software and Services
5.3. Reagents and Consumables
CHAPTER 6 GLOBAL HLA TYPING FOR TRANSPLANT MARKET – BY TECHNOLOGY
6.1. Non-Molecular Assays
6.1.1. Mixed Lymphocyte Culture Assays
6.1.2. Serological Assays
6.2. Molecular Assays
6.2.1. Sequencing-Based Molecular Assays
6.2.1.1. Next-Generation Sequencing
6.2.1.2. Sanger Sequencing
6.2.2. PCR-Based Molecular Assays
6.2.2.1. Sequence-Specific Oligonucleotide-PCR
6.2.2.2. Sequence-Specific Primer-PCR
CHAPTER 7 GLOBAL HLA TYPING FOR TRANSPLANT MARKET – BY APPLICATION
7.1. Research Applications
7.2. Diagnostic Applications
7.3. Others
CHAPTER 8 GLOBAL HLA TYPING FOR TRANSPLANT MARKET – BY END USER
8.1. Commercial Service Providers
8.2. Research Laboratories and Academic Institutes
8.3. Hospitals & Transplant Centers
8.4. Others
CHAPTER 9 GLOBAL HLA TYPING FOR TRANSPLANT MARKET - BY GEOGRAPHY
9.1. Introduction
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.2.3. Mexico
9.2.4. Costa Rica
9.3. South America
9.3.1. Brazil
9.3.2. Argentina
9.3.3. Chile
9.3.4. Columbia
9.3.5. Others
9.4. Europe
9.4.1. U.K.
9.4.2. Germany
9.4.3. France
9.4.4. Italy
9.4.5. Spain
9.4.6. Russia
9.4.7. Netherlands
9.4.8. Switzerland
9.4.9. Poland
9.4.10. Others
9.5. Asia Pacific
9.5.1. China
9.5.2. Japan
9.5.3. India
9.5.4. South Korea
9.5.5. Australia & New Zealand
9.5.6. Malaysia
9.5.7. Singapore
9.5.8. Others
9.6. Middle East & Africa
9.6.1. UAE
9.6.2. Saudi Arabia
9.6.3. Iran
9.6.4. Iraq
9.6.5. Qatar
9.6.6. South Africa
9.6.7. Algeria
9.6.8. Morocco
9.6.9. Nigeria
9.6.10. Egypt
9.6.11. Others
CHAPTER 10 GLOBAL HLA TYPING FOR TRANSPLANT MARKET - COMPANY PROFILES
10.1. Bio-Rad Laboratories, Inc.
10.2. Illumina, Inc.
10.3. Affymetrix, Inc.
10.4. F. Hoffmann-LA-Roche Ltd.
10.5. Luminex Corporation
10.6. Abbott Laboratories, Inc.
10.7. Thermo Fisher Scientific, Inc.
10.8. Qiagen N.V.
10.9. Olerup SSP AB
10.10. Immucor, Inc.
CHAPTER 11 GLOBAL HLA TYPING FOR TRANSPLANT MARKET – COMPETITIVE LANDSCAPE
11.1. Market Share Analysis
11.2. Strategies adopted by top companies
11.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 12 MARKET INSIGHTS
12.1. Industry Experts Insights
12.2. Analysts Opinions
12.3. Investment Opportunities
CHAPTER 13 APPENDIX
13.1. List of Tables
13.2. List of Figures
